登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:000623 证券简称:吉林敖东 公告编号:2025-049 吉林敖东药业集团股份有限公司 关于控股子公司获得药品注册证书的自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 近日，吉林敖东药业集团股份有限公司（以下简称"公司"）控股子公司吉林敖东药业集团延吉股份有限 公司（以下简称"延吉药业"）收到国家药品监督管理局下发的"硫酸特布他林雾化吸入用溶液"的《药品 注册证书》。现就相关情况公告如下： 一、《药品注册证书》的主要内容 1.硫酸特布他林雾化吸入用溶液 药品通用名称：硫酸特布他林雾化吸入用溶液 英文名/拉丁名：Terbutaline Sulfate Nebuliser Solution 主要成份：硫酸特布他林 处方药/非处方药：处方药 受理号：CYHS2401108 证书编号：2025S02676 上市许可持有人名称：吉林敖东药业集团延吉股份有限公司 上市许可持有人地址：吉林省延吉市高新技术开发区长白路389号 剂型：吸入制剂 规格：2ml：5mg 注册分类：化学药品4类 药品 ...

（文章来源：证券日报） 证券日报网讯 9月5日晚间，吉林敖东发布公告称，近日，公司控股子公司吉林敖东药业集团延吉股份 有限公司收到国家药品监督管理局下发的"硫酸特布他林雾化吸入用溶液"的《药品注册证书》。 ...

Group 1 - Huaneng Power announced that its shareholder Hunan Energy Group plans to reduce its stake by up to 20.31 million shares, not exceeding 1% of the total share capital [1] - Ankai Bus reported a production of 1,012 buses in August, a year-on-year increase of 68.06%, with sales of 773 buses, up 46.95% year-on-year [1] - Lianhuan Pharmaceutical received a drug registration certificate for Famotidine injection, classified as a Class 3 chemical drug [1][2] Group 2 - Dongrui Co. reported sales of 94,800 pigs in August, generating revenue of 160 million yuan, a month-on-month decrease of 5.48% [3] - Tiancheng Control's subsidiary received a notification for a passenger car seat assembly project, expected to start production in April 2026 [5] - ST Huluwa obtained a drug registration certificate for Cefodizime capsules, a third-generation broad-spectrum cephalosporin [6] Group 3 - Jiulong Biotech announced the resignation of its Vice Chairman and General Manager Liang Hongjun due to work adjustments [8] - Guanhua High-tech's shareholder plans to reduce its stake by up to 17.50 million shares, not exceeding 1% of the total share capital [9] - Hebei Steel received approval to issue bonds totaling up to 10 billion yuan [10] Group 4 - Yunnan Energy Investment's subsidiaries received a total of 309 million yuan in renewable energy price subsidies [12] - Zhenghong Technology reported sales of 16,800 pigs in August, with a revenue of 22.87 million yuan, showing a year-on-year increase in sales volume of 63.31% [14] - Jilin Aodong's subsidiary received a drug registration certificate for a solution used in asthma treatment [16] Group 5 - Aonong Biological reported a 26.84% year-on-year increase in pig sales volume in August, reaching 150,100 pigs [18] - Xingdesheng announced a share repurchase plan with a budget of 15 to 30 million yuan [20] - Yueyang Lin Paper's Chairman Ye Meng resigned due to work adjustments [22] Group 6 - Kangchen Pharmaceutical's controlling shareholder plans to reduce its stake by up to 4.78 million shares, not exceeding 3% of the total share capital [23] - Changchun Yidong's General Manager Liu Xiaodong resigned due to work adjustments [25] - Zhongzai Resources' subsidiary received a government subsidy of 12.75 million yuan [26] Group 7 - Tianyu Biological reported a 41.89% month-on-month increase in sales revenue from pig sales in August [27] - Changfei Optical's shareholder Draka Comteq B.V. reduced its stake from 10% to 5% [27] - Zhongchuan Technology's Chairman Wu Xingwang resigned due to work adjustments [28] Group 8 - Huakang Clean announced a successful bid for a medical service construction project valued at 131 million yuan [29] - Yuegui Co. plans to establish a wholly-owned subsidiary with a registered capital of 100 million yuan [31] - Baisheng Intelligent's Vice General Manager and Board Secretary Huang Lijun resigned for personal reasons [32] Group 9 - Jiangsu Shuntian will change its stock name to "Suhao Fashion" starting September 10, 2025 [34] - Jiahe Meikang's shareholder plans to reduce its stake by up to 1.3759 million shares, not exceeding 1% of the total share capital [35] - Heng Rui Pharmaceutical received approval for clinical trials of HRS-4729 injection [37] Group 10 - Changfei Optical's shareholder plans to reduce its stake by up to 110,000 shares, not exceeding 0.15% of the total share capital [39] - Yutong Bus reported sales of 4,260 vehicles in August, a year-on-year increase of 16.78% [40] - JinkoSolar received 646 million yuan in renewable energy subsidies in August, a 248% increase year-on-year [41] Group 11 - Beijing Lier signed a strategic cooperation agreement with SenseTime and Xiwang Technology for AI collaboration [43] - Gongdong Medical's controlling shareholder plans to reduce its stake by up to 3% [44] - Zhonghuan Hailu terminated its control change plan and resumed trading [46] Group 12 - Longzi Co. reported a tax payment of 22.27 million yuan due to a tax audit [48] - Guoguang Chain's controlling shareholder plans to reduce its stake by up to 2.99% [49] - Guoxin Technology successfully tested a new high-performance chip for automotive electronics [50] Group 13 - GF Securities reported a cumulative increase in borrowings exceeding 20% of its net assets [51] - China Construction Bank's subsidiary plans to increase capital by 3 billion yuan [52] - Jifeng Technology plans to establish a wholly-owned subsidiary with a capital of 50 million yuan [53] Group 14 - Jiantou Energy received approval for a stock issuance plan to specific investors [54] - Shanghai Laishi's executives plan to collectively increase their holdings by at least 6 million yuan [55] - Wencan Co. reported a fire incident at its subsidiary, with no casualties reported [56]

每经AI快讯，吉林敖东（SZ 000623，收盘价：19.23元）9月5日晚间发布公告称，近日，吉林敖东药业 集团股份有限公司控股子公司吉林敖东药业集团延吉股份有限公司收到国家药品监督管理局下发的《药 品注册证书》。产品名称为"硫酸特布他林雾化吸入用溶液"。 每经头条（nbdtoutiao）——烤肉店里洗头、西湖边开面包店、进军高端酒店……海底捞"不务正业"背 后：子品牌存活率不足50% （记者 曾健辉） 2025年1至6月份，吉林敖东的营业收入构成为：医药行业占比73.63%，连锁药店批发和零售占比 16.59%，食品占比7.39%，其他行业占比1.76%，其他业务占比0.62%。 截至发稿，吉林敖东市值为230亿元。 ...

吉林敖东（000623）(000623.SZ)公告，公司控股子公司吉林敖东药业集团延吉股份有限公司(简称"延吉 药业")收到国家药品监督管理局下发的"硫酸特布他林雾化吸入用溶液"的《药品注册证书》。硫酸特布 他林雾化吸入用溶液的适应症为：缓解支气管哮喘、慢性支气管炎、肺气肿及其它肺部疾病所合并的支 气管痉挛。 ...

格隆汇9月5日丨吉林敖东(000623.SZ)公布，近日，吉林敖东药业集团股份有限公司控股子公司吉林敖 东药业集团延吉股份有限公司(简称"延吉药业")收到国家药品监督管理局下发的"硫酸特布他林雾化吸入 用溶液"的《药品注册证书》。 硫酸特布他林雾化吸入用溶液的适应症：缓解支气管哮喘、慢性支气管炎、肺气肿及其它肺部疾病所合 并的支气管痉挛。 ...

吉林敖东9月5日公告，控股子公司延吉药业近日收到国家药品监督管理局下发的"硫酸特布他林雾化吸 入用溶液"的《药品注册证书》。该药品用于缓解支气管哮喘、慢性支气管炎、肺气肿及其它肺部疾病 所合并的支气管痉挛。此次获得药品注册证书有助于完善公司产品结构，丰富产品种类，增强核心竞争 力。 ...

吉林敖东公告，控股子公司延吉药业近日收到国家药品监督管理局下发的"硫酸特布他林雾化吸入用溶 液"的《药品注册证书》。该药品用于缓解支气管哮喘、慢性支气管炎、肺气肿及其它肺部疾病所合并 的支气管痉挛。此次获得药品注册证书有助于完善公司产品结构，丰富产品种类，增强核心竞争力。 ...

智通财经APP讯，吉林敖东(000623.SZ)公告，公司控股子公司吉林敖东药业集团延吉股份有限公司(简 称"延吉药业")收到国家药品监督管理局下发的"硫酸特布他林雾化吸入用溶液"的《药品注册证书》。 硫酸特布他林雾化吸入用溶液的适应症为：缓解支气管哮喘、慢性支气管炎、肺气肿及其它肺部疾病所 合并的支气管痉挛。 ...

人民财讯9月5日电，吉林敖东（000623）9月5日晚间公告，近日，公司控股子公司吉林敖东药业集团延 吉股份有限公司收到国家药监局下发的"硫酸特布他林雾化吸入用溶液"的《药品注册证书》。 硫酸特布他林雾化吸入用溶液的适应症为缓解支气管哮喘、慢性支气管炎、肺气肿及其它肺部疾病所合 并的支气管痉挛。 ...